International Symposium on Hodgkin Lymphoma
Program at a Glance [This Version: October, 2022]

**Saturday (22.10.2022)**

- **08:45-10:15 Seminars and Workshops**
  - WS: Living beyond Lymphoma (F. van Leeuwen, L. Specht)
  - Seminar: The HL Microenvironment (A. Rosenwald, M. Shipp)
  - Joint EHA-ISHL Symposium (P. Borchmann, M. Dreyling)
  - WS: PET beyond Deauville (S. Barrington, M. Hutchings, C. Ibele)
  - WS: Innovation for Older Patients (P. Brocker, A. Fossad)

- **10:30-12:00 Seminars and Workshops**
  - Seminar: Radiotherapy (C. Baues, J. Yahalom)
  - Seminar: Learning from Pediatric HL (J. Friedberg, C. Maus-Köhler)
  - WS: Bringing Liquid Biopsy to Patients (S. Borchmann, D. Rossi)
  - WS: NLPHL (M. Blinkley, D. Eichenauer, S. Hartmann)

- **12:15-13:45 Openings to the next chapters of lymphoma treatment by BelGen (P. Borchmann)**
  - Welcome and introduction to the topic (P. Borchmann)
  - Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma (P. Brockerit)
  - The challenge of the older patient in lymphoma therapy (G. Collins)
  - New trends in lymphoma therapy: future role of BTKi/CAR-T/bispecific antibodies (P. L. Zinzino)

- **14:30-15:00 Early Stages (M. Andry, H. -T. Elch)**
  - Standard treatment of early-stage HL (J. Radford)
  - Individual risk assessment of RT in HL (R. Hoppe)
  - WS Report: NLPHL (M. Blinkley, D. Eichenauer, S. Hartmann)
  - Oral Abstract Presentations

- **16:00-17:30 CAR T cell therapy in B cell NHL: Status quo and future perspectives by BMS (P. Cramer, C. Scheid)**
  - Status quo of CAR T cell therapy for r/r DLBCL (P. Borchmann)
  - New perspective for the treatment of r/r DLBCL (P. Cramer)
  - CAR T - Lessons Learned (C. Scheid)

**Sunday (23.10.2022)**

- **07:30-09:00 Interactive Case Discussion**
  - Faculty: I. Hillige, Z. Jiastra
  - Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion
    - Greyzone Lymphoma (L. Pinchus)
    - Anti-PD1 Failure (G. Collins)
    - COVID19 Immunity in lymphoma (E. Mellinghoff)
    - Primary progressive HL (A. S. Jacob)

- **09:15-10:15 Emerging Cellular Therapies - a Role in HL?**
  - Cellular Therapy in HL (R. Sauvage)
  - Emerging Indications for cellular therapy (P. Borchmann)
  - t/bd (U. Quintanilla)

- **10:30-12:00 Living beyond Lymphoma**
  - Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors (R. Linton)
  - GHS data on fertility, fatigue and social reintegration and the ongoing EMBRACE study (K. Dehngier)
  - WS Report: Living beyond Lymphoma (F. van Leeuwen, L. Specht)
  - Oral Abstract Presentations

- **12:15-13:45 Checkpoint Inhibition in HL State of the art and future perspectives by MSD (P. Borchmann)**
  - First line therapy of classical Hodgkin Lymphoma - How can immunotherapy improve outcome ? (P. Borchmann)
  - The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin lymphoma (R. T. Tresckow)
  - Strategies to enhance checkpoint inhibition (P. Brockerit)

- **14:00-15:30 Older and Frail Patients (R. Cordoba, A. Evans)**
  - Managing an Older Lymphoma Patient (R. Cordoba)
  - Treatment Allocation in Older HL Patients (A. Evans)
  - WS Report: Innovation for Older patients (A. Fossad, P. Brockerit)
  - Oral Abstract Presentations

- **16:00-17:30 Unraveling Complex Treatment Pathways for Patients with Relapsed/Refractory HL by Takeda**
  - Welcome and Introduction (A. Sureda)
  - Navigating Complex Treatment Decisions in R/R HL (T. Vassiliakopoulos)
  - Challenging Case Study #1 (M. Hutchings)
  - Learning from Real-World Evidence to Inform Treatment Decisions in R/R HL (A. Sureda)
  - Challenging Case Study #2 (M. Hutchings)

**Monday (24.10.2022)**

- **07:30-09:00 Advanced Stages (O. Casasnovas, J. Radford)**
  - Why I recommend: BV-A40 (R. Advani, P. Guided ABTO (A. Fossad)
  - PET-guided bEACOPP (P. Borchmann)
  - Discussion forum (Patient: J. Richardson, Nurse: S. Weiss, Physician: M. Dreyling)
  - Oral Abstract Presentations

- **09:15-10:15 Special Situations in HL**
  - HL in Pregnancy (D. Derickx)
  - HIV-positive HL (D. Baciocchi)
  - aildiST in the era of anti-PD1 (A. Sureda)

- **10:30-12:00 Genomics, Biology & Microenvironment (W. Kriiper, R. Krippers)**
  - Biological Classification of HL by Liquid biopsy (S. Borchmann)
  - Single Cell Transcriptomics of HL (C. Steid)
  - WS Report: Bringing Liquid Biopsy to Patients (S. Borchmann, D. Rossi)
  - Oral Abstract Presentations

  - Hot Off the Press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin lymphoma from ECHLON-1
  - Bridging the gap:Balancing efficacy and toxicity in three challenging case studies
  - Audience Q&A
  - Summary and close

- **14:00-15:30 Relapsed / Refractory HL (R. Advani, C. H. Moszkowit)**
  - 1st Relapse of HL (C. H. Moszkowit)
  - Novel developments in R / R HL (C. Gilani)
  - WS Report: PET beyond Deauville, (S. Barrington, M. Hutchings, C. Ibele)
  - Oral Abstract Presentations

- **16:00-16:30 Farewell**

- **18:00 Opening and Award Ceremony**
  - Keynote Lecture tbd (U. Quintanilla)

- **19:00-20:30 Poster Session and Welcome Reception**
  - New findings and new challenges since last ISHL (S. Ansell)
  - Oral Abstract Presentations
  - Vision Corner
    - Stimulus Talks (M. Shipp, P. Brockerit, G. Collins)
    - Discussion (Chairs: P. Armand, P. Zinzino, Discussants: M. Shipp, P. Brockerit, G. Collins)